An interim analysis from the phase II, open-label ROAR basket trial assessing the combination of BRAF/MEK inhibitor therapy with dabrafenib and trametinib in BRAF V600E-mutated gliomas reported objective response rates of 33% and 69% in the high-grade and low-grade cohorts, respectively (7). The gene discussed is BRAF; the disease is glioma.